Zomedica Inks Deal with Boehringer Ingelheim to Boost TRUFORMA Sales

Strategic Partnership: Zomedica is collaborating with Boehringer Ingelheim, a <strong class="body_output text-content_primary font-semibold" node="[object Object]">global leader in animal health.
Product Integration: The TRUFORMA platform will be integrated into Boehringer Ingelheim&#x27;s <strong class="body_output text-content_primary font-semibold" node="[object Object]">idPPID™ program for equine health.
Financial Goal: The deal is structured to <strong class="body_output text-content_primary font-semibold" node="[object Object]">accelerate TRUFORMA adoption and drive recurring revenue from diagnostic assay sales.

Zomedica Partners With Boehringer Ingelheim to Expand TRUFORMA Reach

Zomedica Corp. announced a strategic collaboration with Boehringer Ingelheim Animal Health USA Inc. on March 18, 2026, in a move designed to expand its footprint in the equine diagnostics market. The partnership centers on integrating Zomedica's TRUFORMA point-of-care system into Boehringer Ingelheim's existing awareness and testing program. This will specifically target the early detection and monitoring of pituitary pars intermedia dysfunction (PPID), a common endocrine disorder in horses.

Deal Targets Accelerated Sales and Recurring Revenue

The collaboration provides Zomedica significant validation by aligning its technology with one of the world's largest animal health companies. By leveraging Boehringer Ingelheim's established idPPID™ program, Zomedica gains a powerful distribution channel to veterinarians. The primary financial objective is to accelerate the installation of TRUFORMA devices, which is expected to create a consistent, recurring revenue stream from the sale of the platform's proprietary equine endogenous ACTH (eACTH) and insulin assays.